Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34636 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Pauline Marolleau und 22 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Leon Berard Center, Lyon, France. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
About 5% of the patients with metastatic colorectal cancers (mCRC) present microsatellite instability (MSI)/deficient mismatch repair system (dMMR). While metastasectomy is known to improve overall and progression‐free survival in mCRC, specific results in selected patients with dMMR/MSI mCRC are lacking. Our study aimed to describe metastasectomy results, characterize histological response and evaluate pathological complete response (pCR) rate in patients with dMMR/MSI mCRC. We retrospectively reviewed data from all consecutive patients with dMMR/MSI mCRC who underwent surgical metastasectomy between January 2010 and June 2021 in 17 French centers. Primary outcome was to assess the pCR rate defined by tumor regression grade (TRG) 0. Secondary endpoints included relapse‐free survival (RFS) and overall survival (OS), and explored TRG as predictive factor for RFS and OS. Among the 88 patients operated, 109 metastasectomies were performed in 81 patients after neoadjuvant treatment [chemotherapy ± targeted therapy (CTT): 69, 85.2%; immunotherapy (ICI): 12, 14.8%], and pCR was achieved in 13 (16.1%) patients. Among the latter, pCR rate were 10.2% in the patients having received CTT (N = 7) and 50.0% in the patients treated with ICI (N = 6). Radiological response did not predict TRG. With a median follow‐up of 57.9 (IQR 34.2‐81.6) months, median RFS was 20.2 (15.4‐not reached) months, median OS was not reached. Major pathological responses (TRG0 + TRG1) were significantly associated with longer RFS (HR 0.12, 95% CI 0.03‐0.55; P = .006). The pCR rate of 16.1% achieved with neoadjuvant treatment in patients with dMMR/MSI mCRC is consistent with previously reported rates in pMMR/MSS mCRC. Immunotherapy showed better pCR rate than chemotherapy ± targeted therapy. Further prospective trials are needed to validate immunotherapy as neoadjuvant treatment in resectable/potentially resectable dMMR/MSI mCRC and identify predictive factors for pCR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Leon Berard Center, Lyon, France.
- Gastroenterology and Hepatology Department, Poitiers University Hospital, University of Poitiers, Poitiers, France.
- Department of Radiation Oncology, Leon Berard Center, Lyon, France.
- Department of Medical Oncology, Saint-Antoine Hospital, Sorbonne Université, AP-HP, and INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Can…
- Normandy Centre for Genomic and Personalized Medicine and Department of Hepatogastroenterology, Normandie Univ, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, Rouen, France.
- Department of Medical Oncology, Val d'Aurelle Center, Montpellier, France.
ORCID-Profile: David Tougeron, Romain Cohen, David Sefrioui, François Ghiringhelli, Thomas Aparicio, Christelle de la Fouchardière
Zitieren
APA
Marolleau, P., Tougeron, D., Allignet, B., Cohen, R., Sefrioui, D., Gallet, B., Dumont, F., Guimbaud, R., Alouani, E., Passot, G., Desolneux, G., Ghiringhelli, F., Marchal, F., Mourthadhoi, F., Coriat, R., Desgrippes, R., Locher, C., Goujon, G., Des Guetz, G., …, & de la Fouchardière, C. (2023). Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study. International Journal of Cancer. https://doi.org/10.1002/ijc.34636
Vancouver
Marolleau P, Tougeron D, Allignet B, Cohen R, Sefrioui D, Gallet B, et al. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study. International Journal of Cancer. 2023. doi:10.1002/ijc.34636
BibTeX
@article{Marolleau2023,
author = {Marolleau, Pauline and Tougeron, David and Allignet, Benoit and Cohen, Romain and Sefrioui, David and Gallet, Blandine and Dumont, Frédéric and Guimbaud, Rosine and Alouani, Emily and Passot, Guillaume and Desolneux, Grégoire and Ghiringhelli, François and Marchal, Frédéric and Mourthadhoi, Farouk and Coriat, Romain and Desgrippes, Romain and Locher, Christophe and Goujon, Gaël and Des Guetz, Gaëtan and Aparicio, Thomas and Paubelle, Etienne and Dupré, Aurélien and de la Fouchardière, Christelle},
title = {Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34636}
}
EUVIMED